According to the latest data from the Hong Kong Stock Exchange, on September 23rd, a shareholder of GENFLEET-B (02595) transferred shares from CITIC Securities Brokerage Hong Kong to Standard Chartered Bank (Hong Kong), with a transfer value of HK$437 million, representing 3.42% of the company.

On September 19th, GENFLEET-B made its debut listing on the Hong Kong Stock Exchange. During trading, the share price reached as high as HK$50.20, representing a 146.20% increase from the issue price, and ultimately closed up 106.47%, with market capitalization approaching HK$15 billion.

According to public information, GENFLEET specializes in developing new therapeutic solutions for oncology (covering various treatment lines for multiple solid tumors) as well as autoimmune and inflammatory diseases. The company has established a product pipeline comprising 8 candidate products, of which 5 are in clinical development stages, including two core products GFH925 and GFH375.